In 2019, Ghana, Kenya and Malawi were selected for a pilot programme called the
Malaria Vaccine Implementation Programme (MVIP), in which four doses of the
medicine were given to residents aged five years and older in selected districts. Two
million children were treated, and not only was a substantial reduction in malaria cases
recorded, but the programme was also responsible for a 13% drop in mortality from all
illnesses. The MVIP pilot programme also showed an ancillary benefit to the RTS,
5/AS0l rollout: patients receiving the vaccine also took other preventative vaccines.
This was the reason for a reduction in child mortality from all illnesses that were
recorded during the programme.
A golden bullet to be deployed with care
5. During the initial RTS, 5/AS0l rollout to run through 2025, Benin, Burundi, the
Democratic Republic of Congo and Uganda will round out the 12 African countries that
will be receiving the malaria vaccine, which includes the three trial countries.
Altogether, 18 million doses of this first-ever malaria vaccine will be distributed in an
effort that has been well-planned and conducted with efficient coordination thus far.
6. However, cautious health officials and organisations are not relying solely on a
vaccine to eradicate malaria in Africa. The WHO notes, "This vaccine has the potential
to be very impactful in the fight against malaria, and when broadly deployed alongside
other interventions, of saving tens of thousands of lives each year." The interventions
that will continue to be observed will be control measures that are now standardly
subscribed for malaria-prone areas: insecticide-treated bed nets, indoor spraying and
preventive treatment for pregnant women. These measures even without a vaccine
have been responsible for the eradication of malaria in some locations and a significant
reduction of malaria-related deaths throughout Africa since 2000.
7. Antimalarial drug resistance is another reason for health officials' preference for
caution over celebration with the vaccine rollout. Over the last decade, the WHO
expressed concern over reports of patient resistance to the malaria treatment drug
Artemisinin in Eritrea, Rwanda, Uganda and Tanzania. The monitoring of antimalarial
drug efficacy is being stepped up to quickly detect and respond to drug resistance.
These caveats aside, there is reason to find in the apparent success of the first anti-
malaria vaccine a cheerful year-end story for 2023.
(Source: https://www.inonafrica.com)
1. Which parts of Africa are mainly troubled by the prevalence of Malaria?
(2)
2. According to the text, how does Anopheles gambiae play transmit malaria? (2)
3. Why does malaria transmission occur throughout the year in Africa?
(2)
4. As stated in the text, which group is most vulnerable to Malaria in Africa?
(2)
5. Describe four ways in which families can gain cost due to malaria infection.
(4)
3